阿斯皮尔肺使强大的变异调用在未能下一代测序质量控制失败的样本
Eleanor Ruth Gray1, Ryan Thomas Evans2, Elizabeth Gillon-Zhang2
1Biofidelity Ltd., Cambridge, UK.
Translational oncology
|October 12, 2025
概括
阿斯皮尔肺部为非小细胞肺癌 (NSCLC) 提供了快速的基因组分析,克服了下一代测序失败. 这种分子测试可以识别可操作的变体,改善患者的治疗结果和治疗选择.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子诊断学 分子诊断学
背景情况:
- 分子测试对于非小细胞肺癌 (NSCLC) 的向治疗选择至关重要.
- 目前的下一代测序 (NGS) 方法面临着诸如高失败率和长时间的周转时间等挑战,延迟了治疗.
- 许多NSCLC患者没有得到及时,适当的向治疗,导致结果较差.
研究的目的:
- 为了评估Aspire Lung的性能,一个快速向的基因组分析分析,与NSCLC的NGS相比.
- 评估Aspire Lung克服NGS故障的能力,并确定可操作的基因组变异.
- 为了确定阿斯皮尔肺在早期NSCLC治疗决策的实用性.
主要方法:
- 198个NSCLC组织样本使用Aspire Lung和NGS进行了测试.
- 队列A包括107个未通过NGS质量控制的样本.
- 队列B包括91个由NGS成功测试的样本;结果进行了比较,并通过正交线解决了差异.
主要成果:
- 在未能通过NGS (A队列) 的样本上,Aspire Lung取得了96%的成功率,在其中47%的样本中确定了变异.
- 在Aspire Lung和成功的NGS测试 (B队列) 之间观察到97%的一致性.
- 在早期NSCLC患者中,Aspire Lung检测到可操作的变体,包括EGFR和ALK.
结论:
- 阿斯皮尔肺部为NSCLC提供快速,可靠的基因组分析,大大减少了周转时间,克服了NSG的局限性.
- 该试验显示出高的成功率和一致率,使得能够及时识别可向突变.
- 阿斯皮尔肺是快速查的一个有价值的工具,特别是在早期的NSCLC,告知治疗策略,如新辅助疗法.
相关概念视频
Next-generation Sequencing
97.7K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.7K
Sanger Sequencing
773.2K
DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
773.2K
RNA-seq
11.7K
RNA sequencing, or RNA-Seq, is a high-throughput sequencing technology used to study the transcriptome of a cell. Transcriptomics helps to interpret the functional elements of a genome and identify the molecular constituents of an organism. Additionally, it also helps in understanding the development of an organism and the occurrence of diseases.
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
11.7K
RACE - Rapid Amplification of cDNA Ends
7.2K
Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...
7.2K
Comparing Copy Number Variations and SNPs
18.6K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
18.6K


